Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Double-blind Placebo-controlled Study To Evaluate The Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard Care For Moderate-to-Severe ARDS Due To Pneumonia Or Other Infections

NCT05947955 is registered in ClinicalTrials.gov with BioAegis Therapeutics Inc. as lead sponsor.

NCT NCT05947955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05947955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Double-blind Placebo-controlled Study To Evaluate The Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard Care For Moderate-to-Severe ARDS Due To Pneumonia Or Other Infections
Lead sponsor
BioAegis Therapeutics Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
October 3, 2024
Completion date
March 1, 2028
Enrollment
600 (estimated)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, infections